文献速递其他结缔组织病

奈非那韦甲磺酸盐:系统性硬化症的潜在疗法

The Antiretroviral Agent Nelfinavir Mesylate: A Potential Therapy for Systemic Sclerosis.
PubMed 文献 · Arthritis Rheumatol · 2017-12-08

本研究探讨FDA已批准的抗逆转录病毒药物奈非那韦甲磺酸盐(NFV)能否老药新用治疗系统性硬化症(SSc)相关肺纤维化。体外实验显示NFV可抑制TGFβ1介导的成纤维细胞向肌成纤维细胞分化,动物模型中显著减轻肺损伤和胶原沉积,支持其作为抗纤维化药物的潜力。

要点

  • NFV通过抑制TGFβ1经典通路阻断肺成纤维细胞向肌成纤维细胞分化。
  • NFV在博来霉素诱导的SSc动物模型中显著减少肺损伤和胶原沉积。
  • NFV的作用机制涉及脱靶蛋白结合,支持其作为抗纤维化药物的可行性。

核心结论

  • NFV通过脱靶蛋白结合阻断TGFβ1介导的成纤维细胞向肌成纤维细胞分化及肺纤维化,支持考虑将该FDA批准药物作为抗纤维化药物。

研究设计与样本

  • 研究使用正常人肺、心室和皮肤成纤维细胞以及SSc患者肺成纤维细胞进行体外实验。
  • 研究采用博来霉素诱导的SSc动物模型评估NFV疗效,并进行计算机模拟分析(in silico)探索脱靶效应。

主要发现

  • NFV通过抑制TGFβ1经典通路,抑制TGFβ1介导的肺成纤维细胞向肌成纤维细胞分化。
  • NFV还抑制皮肤和心室成纤维细胞以及脂肪前体细胞向肌成纤维细胞分化。
  • TGFβ1/雷帕霉素机制靶点通路激活抑制肺成纤维细胞自噬,促进胶原沉积,NFV以剂量依赖方式抵消该效应。
  • 在SSc动物模型中,NFV显著减轻肺损伤和胶原沉积。
  • 计算机模拟分析显示NFV结合蛋白揭示新的潜在有益作用机制,与纤维化已知共同通路一致。

临床怎么用

  • 基于临床前证据,NFV作为已获批药物可能被考虑用于SSc相关肺纤维化的抗纤维化治疗,但需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Transforming growth factor β1 (TGFβ1) is considered a key factor in fibrogenesis, and blocking TGFβ1 signaling pathways diminishes fibrogenesis in animal models. The objective of this study was to determine whether nelfinavir mesylate (NFV), a drug approved by the Food and Drug Administration (FDA) for treating HIV infection, could be repurposed to treat pulmonary fibrosis in patients with systemic sclerosis (SSc). METHODS: Normal human lung, ventricular, and skin fibroblasts as well as lung fibroblasts from SSc patients were used to determine the effects of NFV on fibroblast-to-myofibroblast differentiation mediated by TGFβ1. The efficacy of NFV was also evaluated in an animal model of SSc (bleomycin-induced pulmonary fibrosis). In addition, in silico analysis was performed to determine novel off-target effects of NFV. RESULTS: NFV inhibited TGFβ1-mediated fibroblast-to-myofibroblast differentiation in lung fibroblasts through inhibition of the TGFβ1 canonical pathway. NFV also inhibited differentiation of skin and ventricular fibroblasts and adipocyte precursors into myofibroblasts. Activation of the TGFβ1/mechanistic target of rapamycin pathway inhibited autophagy in lung fibroblasts, favoring collagen deposition, and NFV counteracted this effect in a dose-dependent manner. Moreover, NFV significantly reduced lung injury and collagen deposition in an animal model of SSc. In silico analysis of NFV binding proteins revealed new putative beneficial mechanisms of action, consistent with known common pathways in fibrogenesis. CONCLUSION: NFV abrogates TGFβ1-mediated fibroblast-to-myofibroblast differentiation and pulmonary fibrosis through off-target protein binding, a finding that supports consideration of this FDA-approved medication as an antifibrotic agent.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Sanchez CG, Molinski SV, Gongora R, et al. The Antiretroviral Agent Nelfinavir Mesylate: A Potential Therapy for Systemic Sclerosis. Arthritis Rheumatol. 2017. PMID: 28940894. doi:10.1002/art.40326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。